论文部分内容阅读
近年来国内文献报导原发性肝癌的资料不少,但切除率不高,王成恩等综合国内5所医学院附属医院的肝癌切除率为24.6％,原因是晚期病例较多。过去对晚期肝癌的处理一般较为消极。1961年Miller等介绍经肝动脉插管作抗癌药物灌注治疗晚期肝癌,但该氏未附有治疗病例。国内首见于林氏报导15例,有一定效果。我院外科自1963年3月-1964年1月共收治原发性肝癌24例(经门诊确诊未住院者不包括在内)均经剖腹探查;肝活检病理证实。在24例中只有1例能施行规则性肝极限切除术,14例采用经肝动脉插管抗癌药灌注术,其他不适宜插管或插管失败者以静脉注射抗癌药治疗。现将灌注组为主并附带将静脉注射抗癌药病例作初步总结如下:
In recent years, domestic literature reported that there were many data on primary liver cancer, but the resection rate was not high. The resection rate of liver cancer in Wang Chengen and other hospitals affiliated with 5 medical schools in China was 24.6% due to more advanced cases. In the past, treatment of advanced liver cancer was generally more negative. In 1961, Miller et al. introduced hepatic arterial cannulation as an anti-cancer drug for the treatment of advanced hepatocellular carcinoma, but this group had no treatment. Domestic first met with Lin’s report in 15 cases, with certain results. In our hospital from March 1963 to January 1964, a total of 24 cases of primary hepatocellular carcinoma (not confirmed by outpatient diagnosis) were examined by laparotomy; liver biopsy was confirmed by pathology. Of the 24 patients, only 1 patient was able to perform regular hepatectomy, 14 hepatic arteries were infused with anticancer drugs, and other patients who were not suitable for intubation or intubation were treated with intravenous anticancer drugs. Now the primary perfusion group and incidental intravenous anticancer drug cases are summarized as follows: